[Results of radiation and chemoradiation therapy in esophageal cancer].
Eight therapeutic variants were worked out for 602 patients with esophageal cancer: 61 patients entered in the control group. The latter received routine radiation therapy. The results of therapy of 496 patients were studied. The most promising method was chemoradiotherapy using multifractionation of a daily dose of irradiation, the 4-year survival rate of 20% being achieved. For combination with radiation therapy the following schemes of chemotherapeutic agents were used bleomycin-methotrexate-prospidine, bleomycin-adriamycin-methotrexate, dactinomycin-methotrexate-prospidine, methotrexate-prospidine. Intensive detoxication therapy with parenteral feeding is recommended to decrease the frequency of complications and to improve therapy tolerance.
Azhigaliev
N A
NA
Kusherbaev
S K
SK
Sadykov
S S
SS
Asanov
A A
AA
Fel'dman
S Z
SZ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D005720:Gamma Rays / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008795:Metronidazole / Q000008:administration & dosage; D011447:Prospidium / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D012074:Remission Induction; D013997:Time Factors
D001761:Bleomycin; D008795:Metronidazole; D003609:Dactinomycin; D011447:Prospidium; D004317:Doxorubicin; D008727:Methotrexate
Rezul'taty luchevoĭ i khimioluchevoĭ terapii raka pishchevoda.